For UK HealthTech companies
You need funding to scale, but investors don't understand the NHS market
NHS revenue contracts look nothing like consumer SaaS metrics. Without a commercial story that translates NHS pipeline into investor-familiar terms, you'll lose funding rounds to companies with inferior products and better decks.
Cost of Inaction
Enter your target accounts, live deployments today, average contract value, and achievable conversion rate. The calculator shows the annual revenue gap above today's contracts.
How it breaks down
- Current contracted revenue£270,000
- Revenue at target penetration£324,000
Two minutes, no typing, and I read every one myself.
From Paul
Tell me where that £54,000 is coming from, and I'll come back with the three things to fix first.
A few quick questions, about two minutes, and no typing. I read every one myself and reply with the three things costing you most and where I'd start. If it's useful, we talk. If not, you've still got a clear picture.
No obligation, no sales call unless you ask for one, and nothing automated lands in your inbox.
Paul, Solvable
- The NHS sales cycle is unfamiliar to many investors
- The access route to revenue is not clearly evidenced
- The pitch over-indexes on product over market access
- Milestones are not framed for investor expectations
How to fix it
Build an investor narrative that explains the NHS route to revenue clearly Evidence traction with pilots, references, and a credible access plan Frame the timeline and milestones in terms investors recognise
Frequently asked questions
Why does this problem persist?
Investors used to consumer cycles misread the NHS sales timeline The NHS route to revenue is not explained in terms they trust The story leans on product rather than market access
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.